BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hirakawa A, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: Review and new trial designs. Contemp Clin Trials Commun 2018;12:1-8. [PMID: 30182068 DOI: 10.1016/j.conctc.2018.08.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Tsimberidou AM, Müller P, Ji Y. Innovative trial design in precision oncology. Seminars in Cancer Biology 2020. [DOI: 10.1016/j.semcancer.2020.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Lee KM, Wason J. Including non-concurrent control patients in the analysis of platform trials: is it worth it? BMC Med Res Methodol 2020;20:165. [PMID: 32580702 DOI: 10.1186/s12874-020-01043-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Hamilton G, Hochmair MJ. An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer. Expert Opin Pharmacother 2019;20:1551-61. [PMID: 31328968 DOI: 10.1080/14656566.2019.1643839] [Reference Citation Analysis]
4 Snowdon C, Kernaghan S, Moretti L, Turner NC, Ring A, Wilkinson K, Martin S, Foster S, Kilburn LS, Bliss JM. Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. Trials 2022;23:372. [PMID: 35526005 DOI: 10.1186/s13063-022-06312-x] [Reference Citation Analysis]
5 Park JJH, Ford N, Xavier D, Ashorn P, Grais RF, Bhutta ZA, Goossens H, Thorlund K, Socias ME, Mills EJ. Randomised trials at the level of the individual. Lancet Glob Health 2021;9:e691-700. [PMID: 33865474 DOI: 10.1016/S2214-109X(20)30540-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Walker A. Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare services. J Oncol Pharm Pract 2020;26:2015-9. [PMID: 32957860 DOI: 10.1177/1078155220959428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Sverdlov O, Ryeznik Y, Wong WK. Opportunity for efficiency in clinical development: An overview of adaptive clinical trial designs and innovative machine learning tools, with examples from the cardiovascular field. Contemp Clin Trials 2021;105:106397. [PMID: 33845209 DOI: 10.1016/j.cct.2021.106397] [Reference Citation Analysis]
8 Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, Lester RT, Thorlund K, Mills EJ. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 2019;20:572. [PMID: 31533793 DOI: 10.1186/s13063-019-3664-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 21.0] [Reference Citation Analysis]
9 Rolfo C, Cardona AF, Cristofanilli M, Paz-Ares L, Diaz Mochon JJ, Duran I, Raez LE, Russo A, Lorente JA, Malapelle U, Gil-Bazo I, Jantus-Lewintre E, Pauwels P, Mok T, Serrano MJ; ISLB. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Crit Rev Oncol Hematol 2020;151:102978. [PMID: 32428812 DOI: 10.1016/j.critrevonc.2020.102978] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
10 Bunn V, Liu R, Lin J, Lin J. Flexible Bayesian subgroup analysis in early and confirmatory trials. Contemp Clin Trials 2020;98:106149. [PMID: 32942055 DOI: 10.1016/j.cct.2020.106149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Rodríguez J, Avila J, Rolfo C, Ruíz-Patiño A, Russo A, Ricaurte L, Ordóñez-Reyes C, Arrieta O, Zatarain-Barrón ZL, Recondo G, Cardona AF. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. Oncol Ther 2021;9:89-110. [PMID: 33689160 DOI: 10.1007/s40487-021-00144-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gittings LM, Sattler R. Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies. Fac Rev 2020;9:12. [PMID: 33659944 DOI: 10.12703/b/9-12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Polley MC, Cheung YK. Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology. JCO Precis Oncol 2019;3:PO. [PMID: 32923846 DOI: 10.1200/PO.19.00057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Lavacchi D, Roviello G, D'Angelo A. Tumor-Agnostic Treatment for Cancer: When How is Better than Where. Clin Drug Investig 2020;40:519-27. [PMID: 32307639 DOI: 10.1007/s40261-020-00915-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
15 Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, Al-Chalabi A, Huynh W, Cudkowicz M, Talman P, Van den Berg LH, Dharmadasa T, Wicks P, Reilly C, Turner MR. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol 2021;17:104-18. [PMID: 33340024 DOI: 10.1038/s41582-020-00434-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
16 Lamb JJ, Stone M, D’adamo CR, Volkov A, Metti D, Aronica L, Minich D, Leary M, Class M, Carullo M, Ryan JJ, Larson IA, Lundquist E, Contractor N, Eck B, Ordovas JM, Bland JS. Personalized Lifestyle Intervention and Functional Evaluation Health Outcomes SurvEy: Presentation of the LIFEHOUSE Study Using N-of-One Tent–Umbrella–Bucket Design. JPM 2022;12:115. [DOI: 10.3390/jpm12010115] [Reference Citation Analysis]
17 Vucic S, Wray N, Henders A, Henderson RD, Talman P, Mathers S, Bellgard M, Aoun S, Birks C, Thomas G, Hansen C, Thomas G, Hogden A, Needham M, Schultz D, Soulis T, Sheean B, Milne J, Rowe D, Zoing M, Kiernan MC. MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. Amyotroph Lateral Scler Frontotemporal Degener 2021;:1-8. [PMID: 34590512 DOI: 10.1080/21678421.2021.1980889] [Reference Citation Analysis]
18 Rosenberg L, Levaux H, Levine RL, Shah A, Denmark J, Hereema N, Owen M, Kalk S, Kenny N, Vinson G, Vergilio JA, Mims A, Borate U, Blum W, Stein E, Gana TJ, Stefanos M, Yocum A, Marcus S, Shoben A, Druker B, Byrd J, Burd A. Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial. Ther Innov Regul Sci 2021;55:926-35. [PMID: 33997942 DOI: 10.1007/s43441-021-00277-w] [Reference Citation Analysis]
19 Siden EG, Park JJ, Zoratti MJ, Dron L, Harari O, Thorlund K, Mills EJ. Reporting of master protocols towards a standardized approach: A systematic review. Contemp Clin Trials Commun 2019;15:100406. [PMID: 31334382 DOI: 10.1016/j.conctc.2019.100406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
20 Sotelo-Rodríguez DC, Ruíz-Patiño A, Ricaurte L, Arrieta O, Zatarain-Barrón ZL, Cardona AF. Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies. Ecancermedicalscience 2019;13:936. [PMID: 31552109 DOI: 10.3332/ecancer.2019.936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Bitterman DS, Cagney DN, Singer LL, Nguyen PL, Catalano PJ, Mak RH. Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. J Natl Cancer Inst 2020;112:229-37. [PMID: 31504680 DOI: 10.1093/jnci/djz167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Palmer AC, Plana D, Sorger PK. Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials. Cell Syst 2020;11:449-460.e2. [PMID: 33220857 DOI: 10.1016/j.cels.2020.09.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Herrington WG, Staplin N, Haynes R. Kidney disease trials for the 21st century: innovations in design and conduct. Nat Rev Nephrol 2020;16:173-85. [PMID: 31673162 DOI: 10.1038/s41581-019-0212-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
24 Blucher AS, Mills GB, Tsang YH. Precision oncology for breast cancer through clinical trials. Clin Exp Metastasis 2021. [PMID: 33950412 DOI: 10.1007/s10585-021-10092-0] [Reference Citation Analysis]
25 Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin 2020;70:125-37. [PMID: 32031692 DOI: 10.3322/caac.21600] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
26 Meyer EL, Mesenbrink P, Dunger-baldauf C, Fülle H, Glimm E, Li Y, Posch M, König F. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clinical Therapeutics 2020;42:1330-60. [DOI: 10.1016/j.clinthera.2020.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
27 Taghizadeh H, Zöchbauer-Müller S, Mader RM, Müllauer L, Klikovits T, Bachleitner-Hofmann T, Hoda MA, Prager GW. Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma. Thorac Cancer 2020;11:1979-88. [PMID: 32438515 DOI: 10.1111/1759-7714.13491] [Reference Citation Analysis]
28 Lu CC, Li XN, Broglio K, Bycott P, Jiang Q, Li X, McGlothlin A, Tian H, Ye J. Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. Ther Innov Regul Sci 2021. [PMID: 34160785 DOI: 10.1007/s43441-021-00315-7] [Reference Citation Analysis]
29 Vanderbeek AM, Bliss JM, Yin Z, Yap C. Implementation of platform trials in the COVID-19 pandemic: A rapid review. Contemp Clin Trials 2021;112:106625. [PMID: 34793985 DOI: 10.1016/j.cct.2021.106625] [Reference Citation Analysis]
30 Hirakawa A, Sato H, Igeta M, Fujikawa K, Daimon T, Teramukai S. Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan. Pharm Stat 2022. [PMID: 34994060 DOI: 10.1002/pst.2192] [Reference Citation Analysis]
31 Asano J, Hirakawa A. A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations. Pharm Stat 2020;19:975-1000. [PMID: 32779393 DOI: 10.1002/pst.2049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Cardona AF, Arrieta O, Ruiz-Patiño A, Sotelo C, Zamudio-Molano N, Zatarain-Barrón ZL, Ricaurte L, Raez L, Álvarez MPP, Barrón F, Rojas L, Rolfo C, Karachaliou N, Molina-Vila MA, Rosell R. Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries. Ther Adv Respir Dis 2020;14:1753466620938553. [PMID: 32643553 DOI: 10.1177/1753466620938553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Ampuero J, Romero-Gomez M. Stratification of patients in NASH clinical trials: A pitfall for trial success. JHEP Rep 2020;2:100148. [PMID: 32954243 DOI: 10.1016/j.jhepr.2020.100148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Kang D, S Coffey C, J Smith B, Yuan Y, Shi Q, Yin J. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). Stat Med 2021;40:2893-921. [PMID: 33772843 DOI: 10.1002/sim.8946] [Reference Citation Analysis]
35 Gensheimer MF, Yom SS, Soto N, Dignam JJ, Le QT, Machtay M, Curran WJ. Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology. Int J Radiat Oncol Biol Phys. 2020;108:483-485. [PMID: 32890539 DOI: 10.1016/j.ijrobp.2020.06.056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Di Liello R, Piccirillo MC, Arenare L, Gargiulo P, Schettino C, Gravina A, Perrone F. Master Protocols for Precision Medicine in Oncology: Overcoming Methodology of Randomized Clinical Trials. Life (Basel) 2021;11:1253. [PMID: 34833129 DOI: 10.3390/life11111253] [Reference Citation Analysis]
37 Kesselmeier M, Benda N, Scherag A. Effect size estimates from umbrella designs: Handling patients with a positive test result for multiple biomarkers using random or pragmatic subtrial allocation. PLoS One 2020;15:e0237441. [PMID: 32797088 DOI: 10.1371/journal.pone.0237441] [Reference Citation Analysis]
38 Martins PN, Rizzari MD, Ghinolfi D, Jochmans I, Attia M, Jalan R, Friend PJ; ILTS Special Interest Group “DCD, Preservation and Machine Perfusion”. Design, Analysis, and Pitfalls of Clinical Trials Using Ex Situ Liver Machine Perfusion: The International Liver Transplantation Society Consensus Guidelines. Transplantation 2021;105:796-815. [PMID: 33760791 DOI: 10.1097/TP.0000000000003573] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
39 Lee KM, Brown LC, Jaki T, Stallard N, Wason J. Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. Trials 2021;22:203. [PMID: 33691748 DOI: 10.1186/s13063-021-05150-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Sun LZ, Kang SP, Chen C. Testing monotherapy and combination therapy in one trial with biomarker consideration. Contemp Clin Trials 2019;82:53-9. [PMID: 31201949 DOI: 10.1016/j.cct.2019.06.002] [Reference Citation Analysis]
41 Ayoub G, Chalhoub E, Kourie HR. BRAF: a biomarker not to be missed in glioblastoma. Personalized Medicine. [DOI: 10.2217/pme-2021-0118] [Reference Citation Analysis]
42 Choong Wong S, Joseph S, Capaldi N, Marco MD, Dunne J, Guglieri M, Horrocks I, Straub V, Faisal Ahmed S; UK NorthStar Clinical Network. A survey of the feasibility of developing osteoporosis clinical trials in Duchenne muscular dystrophy: Survey of the opinion of young people with Duchenne muscular dystrophy, families and clinicians. Clin Trials 2021;18:39-50. [PMID: 33012180 DOI: 10.1177/1740774520958395] [Reference Citation Analysis]
43 Selukar S, May S, Law D, Othus M. Stratified randomization for platform trials with differing experimental arm eligibility. Clin Trials 2021;18:562-9. [PMID: 34420417 DOI: 10.1177/17407745211028872] [Reference Citation Analysis]
44 Leonetti A, Boyd L, Giuliani J, Giovannetti E, Garajová I. Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on 'preclinical and early-phase clinical pharmacology'. Expert Rev Clin Pharmacol 2019;12:1033-6. [PMID: 31633383 DOI: 10.1080/17512433.2019.1683446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]